Albuterol in the treatment of acute respiratory distress syndrome: A meta-analysis of randomized controlled trials

Abstract

BACKGROUND:This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome (ARDS).DATA SOURCES: Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: PubMed, Ovid EMBASE, Ovid Cochrane, CNKI, WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials (RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days.RESULTS: Three RCTs involving 646 patients met the inclusion criteria. There was no signifi cant decrease in the 28-day mortality (risk difference=0.09; P=0.07, P for heterogeneity=0.22, I 2 =33%). The ventilator-free days and organ failure-free days were signifi cantly lower in the patients who received albuterol (mean difference=-2.20; P<0.001, P for heterogeneity=0.49, I 2 =0% and mean difference=-1.71, P<0.001, P for heterogeneity=0.60, I 2 =0%).CONCLUSIONS: Current evidences indicate that treatment with albuterol in the early course of ARDS was not effective in increasing the survival, but signifi cantly decreasing the ventilator-free days and organ failure-free days. Owing to the limited number of included trails, strong recommendations cannot be made.

Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview

“…Such procedures do not necessarily involve equipment or products manufactured by the biopharmaceutical, biotechnology, or other health-related industry. However, in cases such as low-dose corticosteroids for acute respiratory distress syndromes we cannot exclude the possibility that the trials not reporting their source of funding were potentially funded by industry, but this had not been disclosed [ 40 ]. We found only one topic where all the available published trials with reported funding disclosed industry support, the evaluation of high-flow nasal cannula in adult acute respiratory failure [ 41 ].…”

Incidence of adult respiratory distress syndrome in trauma patients

“…Several meta-analyses have focused on treatment issues for ARDS. 12 However, they have been inconclusive in terms of the optimal respiratory management, volume replacement, and other treatment options. 13 We therefore performed a systematic review and metaanalysis in patients with posttraumatic ARDS to address some of the open questions addressed above.…”

Association Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis

“…Furthermore, widespread coagulation cascade activation causes microvascular thrombosis and fibroproliferation (Ware and Matthay, 2000). A previous study showed that albuterol could reduce the number of ventilator-free and organ failure-free days, yet it could not improve ARDS patient survival (Wu et al, 2015). At present, despite advancements in our understanding of ARDS pathogenesis, there remains a lack of effective therapy for ARDS (Boyle et al, 2013;Boyle et al, 2014).…”